^

Original-Research: Nynomic AG - von NuWays AG

Einstufung von NuWays AG zu Nynomic AG

Unternehmen: Nynomic AG
ISIN: DE000A0MSN11

Anlass der Studie: Update
Empfehlung: BUY
seit: 21.02.2024
Kursziel: 54.00
Kursziel auf Sicht von: 12 Monaten
Letzte Ratingänderung:
Analyst: Christian Sandherr

Strong Q4 expected // 2024 to be marked by significant growth

Topic: Nynomic should report strong Q4 prelims. More importantly, FY24e
should be marked by strong sales growth and further margin improvements as
well as additional (potentially larger) acquisitions.

Q4 sales are seen to come in at EUR 37.6m (+14% yoy; FY23e sales +4% yoy)
thanks to confirmed calloff dates of formerly delayed orders and several
new projects within structurally growing markets. This should partially
compensate for the flattish top-line development during 9M. As a result of
the expected strong sales figure and the ability to book high-margin
development revenues (typically due towards the end of a year), the EBIT
margin in the fourth quarter is seen to jump to 19.8% (+5.9pp yoy; FY23e
margin +0.1pp yoy), thus reaching a new record high.

Returning to strong growth in 2024. For FY24e, we expect Nynomic to grow
sales by almost 17% yoy. Besides consolidation effects from the acquisition
of art photonics (3.8pp of FY24 group growth), the company is seen to reap
the fruits from several products gaining traction. For instance, the first
large order for Spectral Engines' TactiScan (handheld device to detect
drugs) should contribute a mid single-digit million amount in 2024 alone
(eNuW). Nynomic is also seen to show strong growth within its agricultural,
semiconductor and medtech end markets.

Thanks to a positive operating leverage, so far loss-making businesses
scaling up and a growing share of recurring and high-margin software
revenues (related to hardware sales), Nynomic looks set to further expand
its EBIT margin to 13.7% (+0.7pp yoy).

Additional inorganic tailwinds in the cards. As per its Buy & Build
strategy, Nynomic should be looking to acquire 1-2 additional companies
during the next six months, in our view. The focus of those transactions
should lie on expanding its technology and solutions portfolio. Thanks to
its inherently cash flow generating business model and the EUR 18.9m capital
increase in May last year, the company should be equipped with sufficient
financial firepower to be considering larger targets with up to EUR 20m
sales.

This, coupled with expected organic double-digit sales CAGR during the
mid-term (eNuW), bodes well with the company's mid-term targets of EUR 200m
sales with an EBIT margin of 16-19%.

BUY with an unchanged EUR 54 PT based on DCF. Nynomic remains one of our
top-picks for 2024.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/28949.pdf
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.

Kontakt für Rückfragen
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.
Kontakt für Rückfragen
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------übermittelt durch die EQS Group AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

°


Quelle: dpa-AFX